S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE.

• J.-M. Michot,
• A. Mehta,
• F. Samaniego,
• E. Bachy,
• P. L. Zinzani,
• A. Prica,
• G. P. Colins,
• V Ribrag,
• N. Wagner-Johnston,
• D. El-Sharkawi,
• O. A. O’Connor,
• R. Wilcox,
• L. Wang,
• L. Wilson,
• M. Sims,
• J. A. Taylor,
• H. N. Keer,
• F. Foss

Affiliations

J.-M. Michot

1 Department of Hematology, Institut Gustave Roussy, Villejuif, France

A. Mehta

2 University of Alabama at Birmingham, Birmingham

F. Samaniego

3 The University of Texas MD Anderson Cancer Center, Houston, United States of America

E. Bachy

4 Hematology Department, Lyon Sud Hospital, Lyon, France

P. L. Zinzani

5 Institute of Hematology “L. e A. Seràgnoli”, Bologna, Italy

A. Prica

6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada

G. P. Colins

7 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

V Ribrag

1 Department of Hematology, Institut Gustave Roussy, Villejuif, France

N. Wagner-Johnston

8 Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States of America

D. El-Sharkawi

9 The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom

O. A. O’Connor

10 University of Virginia, Charlottesville

R. Wilcox

11 University of Michigan Medical School, Ann Arbor

L. Wang

12 Astex Pharmaceuticals, Inc., Pleasanton, United States of America

L. Wilson

12 Astex Pharmaceuticals, Inc., Pleasanton, United States of America

M. Sims

13 Astex Pharmaceuticals, Cambridge, United Kingdom

J. A. Taylor

12 Astex Pharmaceuticals, Inc., Pleasanton, United States of America

H. N. Keer

12 Astex Pharmaceuticals, Inc., Pleasanton, United States of America

F. Foss

14 Yale Cancer Center, New Haven, United States of America